Transgender Children’s Healthcare in the UK – Navigating the Complexities As a Transgender Advocacy Organisation, we receive many requests from…
Browsing: GnRHa
At Translucent, we are dedicated to providing an objective look at the wealth of evidence worldwide on the use of GnRH analogues (puberty blockers) in order to:
- Address fundamentally flawed assumptions: Our articles address the fundamentally flawed assumption that the use of GnRH analogues alleviates gender dysphoria.
- Challenge NICE reviews: We challenge NICE reviews and the NHS for making a deliberate attempt to provide “evidence” that PBs are not effective.
- Advocate for defined use/needs/outcomes: Our articles advocate for clearly defined use/needs/outcomes of these interventions, assuming that these treatments are actually accessible and not gatekept to the same extent as currently.
- Offer an objective look: We aim to take an objective look at the wealth of evidence worldwide on the use of GnRH analogues (puberty blockers).
Our Year End Operational Review highlights TransLucent’s advocacy for the trans and non-binary community, including meetings with government officials to discuss healthcare and policy reform. The review also acknowledges financial challenges, celebrates the distribution of their report “TRANS: A Community Under Attack,” and outlines TransLucent’s position on the Cass Report, puberty blockers, and single-sex spaces.
Continue Reading TransLucent Year End Operational Review
TransLucent’s position statement argues against the ban on puberty blockers (GnRH analogues) for young trans people, citing insufficient evidence and potential bias in the Cass Review. Continue Reading TransLucent Puberty Blocker (GnRH Analogues) Position Statement
